Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer After Prior Anthracycline-based Adjuvant Chemotherapy

NCT02054338 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT02054338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02054338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer After Prior Anthracycline-based Adjuvant Chemotherapy
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2006
Completion date
February 28, 2015
Enrollment
1,004 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer